Trial · NCT02475265
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
NCT02475265, Phase 2, Completed, Massachusetts General Hospital; results first posted 2019-07-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa. Trials, record NCT02475265. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02475265
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
- NCT number
- NCT02475265
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 11 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Anorexia Nervosa, Osteoporosis
- Interventions
- estradiol 0.045 mg/levonorgestrel 0.015mg
- First posted
- 2015-06-18
- Last updated
- 2019-07-22
- Results first posted
- 2019-07-22
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) | 6 months | Percent change in lumbar spine bone mineral density after six-months. Lumbar spine bone mineral density measured by dual energy x-ray absorptiometry. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) | 6 months | percent change | MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) | Estradiol 0.045mg/Levonorgestrel 0.015mg | 2.0 | Standard Error 0.8 | percent change |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Estradiol 0.045mg/Levonorgestrel 0.015mg | 11 | |
| Overall Study | COMPLETED | Estradiol 0.045mg/Levonorgestrel 0.015mg | 8 | |
| Overall Study | NOT COMPLETED | Estradiol 0.045mg/Levonorgestrel 0.015mg | 3 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Estradiol 0.045mg/Levonorgestrel 0.015mg | 3 | 11 | |
| other | Breast tenderness | Reproductive system and breast disorders | Estradiol 0.045mg/Levonorgestrel 0.015mg | 1 | 11 | |
| other | Patch site irritation | Skin and subcutaneous tissue disorders | Estradiol 0.045mg/Levonorgestrel 0.015mg | 3 | 11 | |
| other | Vomiting | Gastrointestinal disorders | Estradiol 0.045mg/Levonorgestrel 0.015mg | 1 | 11 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Estradiol 0.045mg/Levonorgestrel 0.015mg | 0 | 11 |
| Total, other adverse events | Estradiol 0.045mg/Levonorgestrel 0.015mg | 7 | 11 |
| Total, serious adverse events | Estradiol 0.045mg/Levonorgestrel 0.015mg | 0 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R03DK106410 | Transdermal Estrogen in Older Premenopausal Women with Anorexia Nervosa | FAZELI, POUNEH KHADEJEH | MASSACHUSETTS GENERAL HOSPITAL | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2015 to 2016 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02475265
GET https://conductscience.org/api/trials/v1/NCT02475265/registered